Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.
Neuren Pharmaceuticals Limited has announced a new on-market share buy-back of its ordinary fully paid shares listed on the ASX under the code NEU. The move signals that the board sees value in the current share price and is willing to deploy capital to repurchase equity, which may support earnings per share and provide a potential uplift for existing shareholders by reducing the number of shares on issue.
The buy-back notification formalises Neuren’s authority to begin acquiring its own shares on the open market in accordance with ASX requirements. While specific terms such as total size or timing were not disclosed in the notice, the decision underscores management’s confidence in the company’s outlook and may influence trading liquidity and capital management perceptions among investors.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code NEU, with its primary securities being ordinary fully paid shares. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of neurological and related therapies for global healthcare markets.
Average Trading Volume: 354,351
Technical Sentiment Signal: Sell
Current Market Cap: A$1.59B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.